LASERSIGHT ANNOUNCES SECOND QUARTER 1999 RESULTS
                    -Provides Update on FDA Approval Process-

Winter Park, FL. (August 9, 1999) - LaserSight Incorporated (NASDAQ: LASE) today
announced financial results for the second quarter and six months ended June 30,
1999. Technology related and total revenues increased over the quarters ended
March 31, 1999 and June 30, 1998.

         Revenues  for the second  quarter  increased  approximately  8% to $5.3
million from $4.9 million in the second quarter of 1998. The Company reported a
net loss of $3.5 million, or $0.21 per share, compared to a net loss of $1.8
million reported for the second quarter of 1998 before the additional $2.4
million loss attributable to common shareholders for that quarter of 1998,
reflecting the effects of premiums, accretion and conversion discounts on the
redemption of Series B Preferred Stock and the issuance of Series C and D
Preferred Stock. The loss per share in the second quarter of 1998 was $0.34. The
average common shares outstanding were 16,155,000 during the second quarter of
1999 compared to 12,626,000 in the second quarter of 1998.

         Compared to the first quarter of 1999, revenues increased approximately
8% from $4.9 million. The Company's net loss for the second quarter of 1999 was
comparable to the net loss reported in the first quarter of 1999, of $3.3
million, or $0.25 per share.

         Revenues for the six months ended June 30, 1999 increased approximately
11% to $10.2 million from $9.2 million in the comparable period of 1998. The
Company reported a net loss of $6.8 million for the six months ended June 30,
1999, or $0.46 per share, compared to a net loss of $3.7 million reported for
the six months ended June 30, 1998 before the additional $3.6 million loss
attributable to common shareholders for that period of 1998, reflecting the
effects of premiums, accretion and conversion discounts on the redemption of
Series B Preferred Stock and the issuance of Series C and D Preferred Stock. The
loss per share for the six months ended June 30, 1998 was $0.64. The average

<PAGE>

common shares outstanding were 14,794,000 during the six months ended June 30,
1999 and 11,478,000 in the comparable period of 1998.

         During  the  three  months  ended  June 30,  1999 the  Company  sold 16
refractive laser systems, compared to 15 systems sold during the second quarter
of 1998. Terms of sales continued to improve, with an increase in average
selling price of the LaserScan LSX excimer laser system of approximately 20 %
net of commissions over the first quarter of 1999. In addition, the Company
began shipment of its UltraEdge (TM) Keratome Blades in the U.S., Canada and
other international markets in late July. The blades are manufactured for the
Company by Becton Dickinson (NYSE: BDX) as part of a joint venture first
announced in May.

         Michael R. Farris, chief executive officer, commented, " We are pleased
to report an increase in revenues for the second quarter, along with the recent
shipment of our UltraEdge Keratome Blades". Mr. Farris continued, "Through our
joint venture with Becton Dickinson, our manufacturing partner, we have
increased our available manufacturing capacity to meet the refractive market's
growing demand for these products".

         Separately,  the  Company  provided  an update on the status of the FDA
approval process for its excimer laser technology. The Company stated that its
PMA application is on track for third or fourth quarter approval. The FDA has
waived review by its Ophthalmic Devices Advisory Panel, as the Company's
clinical data was found to meet or exceed the requirements of the FDA's Guidance
Document.  The review of the clinical data and a biomonitoring audit have been
successfully completed. The FDA's Good Manufacturing Practices (GMP) inspection
is currently underway. Final FDA approval is expected within 30 - 60 days
following successful completion of the GMP audit, during which the approved
labeling is defined.

         LaserSight Incorporated provides quality technology solutions for laser
refractive surgery and other innovative applications, mainly in the vision
correction industry. The Company sells its products in more than 30 countries.
In the United States, LaserSight's refractive scanning laser system has a
pending pre-market approval application with the U.S. Food and Drug
Administration and is not yet commercially available in this market.

<PAGE>

         This press release contains forward-looking statements regarding future
events and future performance of the Company, including statements with respect
to anticipated sales revenue, which involves risks and uncertainties that could
materially affect actual results. Investors should refer to documents that the
Company files from time-to-time with the Securities and Exchange Commission for
a description of certain factors that could cause the actual results to vary
from current expectations and the forward looking statements contained in this
press release. Such filings include, without limitation, the company's Form
10-K, Form 10-Q and Form 8-K reports.

Following are selected LaserSight financial results:

                         (in 000s except per share data)
<TABLE>
<CAPTION>

                                                              THREE MONTHS ENDED          SIX MONTHS ENDED
                                                                   June 30,                   June 30,

                                                             1999            1998         1999         1998

<S>                                                        <C>               <C>         <C>           <C>
Total Revenues                                             $ 5,261           4,949       10,150        9,192
Cost of Revenues                                             2,337           1,787        4,417        3,051
Gross Profit                                                 2,924           3,162        5,733        6,141
Research, Development and Regulatory                           709             744        1,490        1,561
Selling, General  & Administrative                           5,856           4,185       11,260        7,932
Loss from Operations                                        (3,641)         (1,767)      (7,017)      (3,352)
Other Income (Expense)                                         190             (62)         246         (130)
Income tax (Benefit) Expense                                    --             (78)          --          232
Net Loss                                                    (3,451)         (1,751)      (6,771)      (3,714)
Preferred Stock Accretions / Dividends
     and Conversion Discounts                                   --          (2,487)          --       (3,611)
Loss Attributable to Common Shareholders                    (3,451)         (4,238)      (6,771)      (7,325)
Loss per Common Share - Basic and Diluted                    (0.21)          (0.34)       (0.46)       (0.64)
Weighted Average Number of Shares Outstanding               16,155          12,626       14,794       11,478

SELECTED BALANCE SHEET DATA (in 000s):

                                                                     June 30, 1999         December 31, 1998
Cash and Cash Equivalents                                              $    14,664                $    4,438
Accounts and Notes Receivable (Current), Net                                 9,821                     9,418
Total Current Assets                                                        33,514                    22,717
Total Current Liabilities                                                    7,573                     7,842
Long-Term Obligations                                                          553                       560
Stockholders' Equity                                                        44,400                    34,015
</TABLE>